Filtered By:
Cancer: Prostate Cancer
This page shows you your search results in order of relevance. This is page number 2.
Order by Relevance | Date
Total 879 results found since Jan 2013.
Targeting the androgen receptor with siRNA promotes prostate cancer metastasis through enhanced macrophage recruitment via CCL2/CCR2‐induced STAT3 activation
Increased CCL2 expression in prostate cancer (PCa) cells enhanced metastasis via macrophage recruitment. However, its linkage to androgen receptor (AR)‐mediated PCa progression remains unclear. Here, we identified a previously unrecognized regulation: targeting AR with siRNA in PCa cells increased macrophage recruitment via CCL2 up‐regulation, which might then result in enhancing PCa invasiveness. Molecular mechanism dissection revealed that targeting PCa AR with siRNA promoted PCa cell migration/invasion via CCL2‐dependent STAT3 activation and epithelial–mesenchymal transition (EMT) pathways. Importantly, pharmaco...
Source: EMBO Molecular Medicine - August 27, 2013 Category: Molecular Biology Authors: Kouji Izumi, Lei‐Ya Fang, Atsushi Mizokami, Mikio Namiki, Lei Li, Wen‐Jye Lin, Chawnshang Chang Tags: Research Article Source Type: research
A novel, anisamide-targeted cyclodextrin nanoformulation for siRNA delivery to prostate cancer cells expressing the sigma-1 receptor
In this study, a cationic cyclodextrin derivative was synthesized to complex siRNA. The nanoparticle was then further modified by exploiting the ability of the β-cyclodextrin cavity to form an inclusion complex with the hydrophobic molecule adamantane. PEGylated adamantane derivatives were synthesized with and without the anisamide-targeting ligand on the terminal end of the PEG chain. Anisamide is known to bind specifically to the sigma receptor which is overexpressed on the surface of prostate cancer cells. The resulting nanocomplexes were slightly cationic and less than 300nm in size. They successfully protected siRNA ...
Source: International Journal of Pharmaceutics - January 12, 2016 Category: Drugs & Pharmacology Source Type: research
Folate-targeted amphiphilic cyclodextrin.siRNA nanoparticles for prostate cancer therapy exhibit PSMA mediated uptake, therapeutic gene silencing in vitro and prolonged circulation in vivo
This study highlights the ability of incorporating a folate ligand into CD.siRNA nanoparticles to allow for targeted delivery of siRNA to prostate cancer cells via the PSMA. Graphical abstract
Source: Nanomedicine: Nanotechnology, Biology and Medicine - August 27, 2016 Category: Nanotechnology Source Type: research
Folate-targeted amphiphilic cyclodextrin nanoparticles incorporating a fusogenic peptide deliver therapeutic siRNA and inhibit the invasive capacity of 3D prostate cancer tumours
Publication date: 30 October 2017 Source:International Journal of Pharmaceutics, Volume 532, Issue 1 Author(s): James C. Evans, Meenakshi Malhotra, Katrina Sweeney, Raphael Darcy, Colleen C. Nelson, Brett G. Hollier, Caitriona M. O’Driscoll The main barrier to the development of an effective RNA interference (RNAi) therapy is the lack of a suitable delivery vector. Modified cyclodextrins have emerged in recent years for the delivery of siRNA. In the present study, a folate-targeted amphiphilic cyclodextrin was formulated using DSPE-PEG5000-folate to target prostate cancer cells. The fusogenic peptide GALA was included i...
Source: International Journal of Pharmaceutics - September 22, 2017 Category: Drugs & Pharmacology Source Type: research
Recent advances in siRNA delivery systems for prostate cancer therapy
Curr Pharm Biotechnol. 2021 Jun 15. doi: 10.2174/1389201022666210615123211. Online ahead of print.ABSTRACTThe critical problems of conventional prostate cancer therapeutic strategies like nonspecific toxicity and multi-drug resistance prompted the development and application of countless nanoparticle-based siRNA therapeutics. The main challenges to siRNA-based therapeutics becoming a new paradigm in the treatment of prostate cancer stem from the lack of safe and effective delivery systems, immune system stimulation, poor knowledge of nano-bio interactions, and limitations concerning designing, manufacturing, clinical trans...
Source: Current Pharmaceutical Biotechnology - June 16, 2021 Category: Biotechnology Authors: Shahin Aghamiri Pourya Raee Shiva Shahmohamadnejad Sasan Shabani Jaber Ghorbani Marzieh Sameni Mohammad Taha Ebrahimi Source Type: research
Synthesis of KUE-siRNA conjugates for prostate cancer cell-targeted gene silencing
Chembiochem. 2021 Jul 14. doi: 10.1002/cbic.202100243. Online ahead of print.ABSTRACTThe delivery of siRNAs to selectively target cells posed a great challenge in RNAi-based cancer therapy. The lack of suitable cell-targeting methods seriously restricted the advance in delivering siRNAs to extrahepatic tissues. Based on prostate-specific membrane antigen (PSMA)-targeting ligands, we here synthesized a series of KUE-siRNA conjugates and verified their effective cell uptake and gene silencing properties in prostate cancers. The results indicated that the KUE-siRNA conjugates could selectively enter PSMA + LNCaP cells, eventu...
Source: Chembiochem - July 15, 2021 Category: Biochemistry Authors: Zhen Xi Chao Yang Dejun Ma Liqing Lu Xing Yang Source Type: research
